Lexicon Pharmaceuticals Inc

NASDAQ:LXRX  
2.84
+0.15 (+5.58%)
Regulatory, Earnings Announcements

Lexicon Pharmaceuticals Inc - Net Loss For Q2 Of 2022 Was $24.6 Million, Or $0.16 Per Share

Published: 08/02/2022 21:15 GMT
Lexicon Pharmaceuticals Inc (LXRX) - Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update.
Lexicon Pharmaceuticals - Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA,with PDUFA Action Date Anticipated in May 2023.
As of June 30, 2022, Lexicon Had $62.0 Million in Cash and Investments.
Net Loss for Q2 of 2022 Was $24.6 Million, Or $0.16 per Share.
Q2 Earnings per Share View $-0.16 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0.1 Million
Adjusted EPS is expected to be -$0.13

Next Quarter Revenue Guidance is expected to be $0.1 Million
Next Quarter EPS Guidance is expected to be -$0.13

More details on our Analysts Page.